Johnson & Johnson Cuts 56 Jobs Amid Abandonment of $20B Orthopedics IPO Plan

May 28, 2026 10:39 CST Updated 10:39

Johnson & Johnson

Medical Device R&D and Manufacturer

On May 27, 2026, WARN notices from New Jersey, USA, indicated that healthcare giant Johnson & Johnson will lay off 56 employees at its global headquarters in New Brunswick. The layoffs will officially take effect on August 21, 2026.This marks Johnson & Johnson's first round of layoffs at this campus this year, just one year after the layoff of 231 employees at the same site in autumn 2024, as the pace of the company's business restructuring continues to accelerate.

Official Response: Layoffs are Supporting Measures for the Orthopedics Business Spin-off

Johnson & Johnson officially confirmed that this workforce optimization is a supporting measure accompanying the divestiture of its orthopedics business and strategic restructuring. The company stated that it will dynamically adjust its organizational and cost structures, streamline redundant business costs, and safeguard the company's investment in innovation and sustainable development.

This adjustment follows Johnson & Johnson's major restructuring plan announced in October 2025. At that time, the company announced plans to spin off its core orthopedics division, DePuy Synthes, to operate it as an independent entity within 18 to 24 months. This business specializes in orthopedic implant devices and related equipment, reporting $9.2 billion in revenue for fiscal year 2024 and accounting for 29% of the MedTech segment's total revenue.

Industry sources indicate that Johnson & Johnson has adjusted its disposal strategy for its orthopedics business. As of February 2026, the company has abandoned its spin-off listing plan, shifting instead to an outright sale of the entire segment, which is valued at over $20 billion. Currently, several leading private equity firms are planning a joint bid, while Johnson & Johnson is compiling its financial documents to prepare for engagement with potential investors.

New Jersey Pharmaceutical Layoffs Continue to Mount as Industry Restructuring Becomes the New Normal

Johnson & Johnson’s layoffs are not an isolated case. As a major hub for U.S. pharmaceutical companies, New Jersey has recently seen leading pharma firms frequently initiate workforce reductions and organizational restructuring, with cost-cutting and corporate restructuring becoming the new industry norm.

Novartis's US headquarters in East Hanover has completed three rounds of layoffs in 2026, cumulatively reducing its workforce by 174 employees, as it continues to implement the global 8,000-job reduction plan announced in 2022. The campus previously eliminated 427 positions in a single round in March 2025, underscoring the significant intensity of its restructuring efforts.

Bristol Myers Squibb has intensified its cost-cutting efforts. Year-to-date in 2025, the Lawrenceville facility alone has conducted two rounds of layoffs, eliminating 453 positions, bringing the cumulative annual headcount reduction to over 1,700. The company plans to achieve cost savings exceeding $2 billion by 2027, while continuing to optimize its profitability structure.

Additionally, in May 2026, Amicus Therapeutics, acquired by BioMarin for $4.8 billion, also laid off 58 employees in New Jersey, serving as a typical example of post-merger integration and optimization in the pharmaceutical industry.

Industry Observation: Strategic Focus and Cost Reduction & Efficiency Improvement Emerge as Core Drivers

Industry analysis indicates that the concentrated layoffs and optimization efforts among leading global pharmaceutical companies primarily revolve around two major trends:Focus on High-Value Segments, Optimize Business PortfolioandStrictly Control Operating Costs, Stabilize Profitability。

For Johnson & Johnson, sluggish growth in its orthopedics business is the core reason for the divestiture. In 2025, this segment grew at a mere 1.1%, ranking last among its four medical technology segments, while the cardiovascular business achieved a growth rate of 12.6%. Following the divestiture of the orthopedics unit, Johnson & Johnson will focus on three high-growth sectors: cardiovascular, surgery, and vision. The proportion of high-value assets will increase from 50% to over 70%, significantly strengthening its core competitiveness.

The global pharmaceutical industry is currently facing pressures including escalating R&D costs, the clustered expiration of drug patents, and intensifying market competition. Streamlining organizational structures and reducing costs to balance R&D investment with profitability has become a standard strategy for international pharmaceutical companies to navigate industry cycles and ensure steady development.

As of now, Johnson & Johnson has not yet announced the final divestment plan for its orthopedics business or subsequent workforce adjustment plans. With the ongoing cost-cutting and restructuring initiatives among pharmaceutical companies, the wave of structural optimization across the global pharmaceutical and medical industry is expected to persist.

Reference Source:https://www.fiercepharma.com/pharma/jj-separates-its-orthopedics-business-it-lays-56-new-jersey

Scan the WeChat QR code to add the editor of the "Biologics Circle". Eligible individuals will be approved to join.

Biologics WeChat Group!

Please specify: Name + Research Direction!

Version

Right

Sound

Clear

All reposted articles on this official account are for informational purposes only, with the source and author clearly cited. Should any media outlet or individual object to the reposting of their content, please contact us at cbplib@163.com, and we will promptly remove it. The views expressed in all articles are solely those of the authors and do not necessarily reflect the position of this account.